-
Feb 26, 2021- Phase 3 Program of IMU-838 in Relapsing-Remitting Multiple Sclerosis Expected to Begin in the Second Half of 2021-
-
Feb 18, 2021- Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared to Baseline -
-
Feb 17, 2021- Clinical Activity of IMU-838 Confirmed Based on Multiple Secondary Endpoints, Including Clinically Meaningful Improvements in Time to Clinical Recovery and Clinical Improvement -
-
Jan 5, 2021- Management Provides Update on Timing of Data for IMU-838 in Primary Sclerosing Cholangitis -
-
Dec 14, 2020
-
Nov 17, 2020- Initial Appointments Include Internationally Recognized Experts: Fred D. Lublin, M.D.; Bruce E. Sands, M.D., M.S.; Jerrold R. Turner, M.D., Ph.D. and Paul J. Utz, M.D. -
-
Nov 5, 2020- Released Very Positive Phase 2 Data for IMU-838 in Relapsing-Remitting Multiple Sclerosis; Company to Submit End-of-Phase 2 Meeting Requests to Regulatory Authorities at the End of Q1 2021 -
-
Nov 2, 2020- Top-Line Data Expected in Q1 2021 -
-
Oct 20, 2020- European Investment Bank and Immunic sign a financing agreement of up to €24.5 million to support the development of Immunic's lead asset, IMU-838, in moderate COVID-19
-
Sep 11, 2020- Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations -
-
Aug 2, 2020- Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis -
-
Jul 27, 2020- Study Being Conducted in Collaboration with University Hospitals Coventry and Warwickshire NHS Trust -
-
Jun 22, 2020
-
May 19, 2020- Presentation Will Include Preclinical Data of IMU-838 Against SARS-CoV-2 as Well as First Pharmacokinetic Data From the Ongoing Phase 1 Clinical Trial of IMU-935 -
-
Apr 21, 2020- In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit Viral Replication of SARS-CoV-2 -
-
Apr 17, 2020
-
Mar 16, 2020- Top-Line Data from Phase 2 EMPhASIS Trial in Relapsing-Remitting Multiple Sclerosis Expected in Third Quarter 2020 -
-
Jan 8, 2020Phase 1 Clinical Studies to begin in First Half of 2020
-
Dec 4, 2019IMU-856 has the potential to address one of the putative root causes of inflammatory bowel disease without impairing the immune system
-
Oct 10, 2019- Milestone Achieved Nine Months Ahead of Initial Schedule; Top-Line Data Expected in Q3 2020 -
-
Sep 11, 2019Preclinical Findings Confirm Favorable Profile of IMU-838 as Compared to Teriflunomide in the Potential Treatment of Relapsing-Remitting Multiple Sclerosis
-
Sep 5, 2019- Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg Dose -
-
Aug 12, 2019- Study Being Conducted in Collaboration with Investigators at Arizona State University and the Mayo Clinic -
-
Jun 21, 2019- Phase 2 Trial in Relapsing-Remitting Multiple Sclerosis Expected to be the First Efficacy Read-Out of IMU‑838; Top-line Data Anticipated in Q3 2020 -
-
Jun 4, 2019- Results confirm IMU-935 as a potent inverse agonist of RORϒt with an IC50 of 24 nM, leading to potent inhibition of Th17 differentiation while allowing normal thymocyte maturation -
-
Apr 12, 2019- Developing Oral Therapies with Best-in-Class Potential -
-
Mar 27, 2019Of the Votes Received to Date, More than 98% are Voting in Favor of the Business Combination
-
Mar 4, 2019
-
Jan 7, 2019Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets
-
Nov 5, 2018Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease
-
Apr 26, 2018First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial with Immunic’s oral investigational drug IMU-838, a best-in-class DHODH inhibitor
-
Jan 11, 2018FDA has granted IND approval for Immunic’s oral investigational drug IMU-838
-
Dec 12, 2017Two phase 1 studies for IMU-838 in healthy volunteers have been completed
-
Sep 5, 2017Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10 million (USD 12 million) in equity financing
-
Feb 1, 2017Series A financing round extended to EUR 21.7 Million